{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:18:00Z","timestamp":1784585880433,"version":"3.55.0"},"reference-count":19,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":202,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetic Medicine"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Aims\u2002<\/jats:bold> To define the number of people in Tayside, Scotland (population 349\u2003303) with Type 2 diabetes who use metformin, the incidence of contraindications to its continued use in these people and the proportion that discontinued metformin treatment following the development of a contraindication.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Retrospective cohort study of the incidence of contraindications to metformin in all patients with Type 2 diabetes using metformin from January 1993 to June 1995. The contraindications of acute myocardial infarction, cardiac failure, renal impairment and chronic liver disease were identified by: the regional diabetes information system, biochemistry database and hospital admissions database and a database of all encashed community prescriptions.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> One thousand eight hundred and forty seven subjects (26.3% of those with Type 2 diabetes) redeemed prescriptions for metformin. Of these, 3.5% were admitted with an acute myocardial infarction (71 episodes); 4.2% were admitted with cardiac failure (114 episodes); 21.0% received metformin and loop diuretics for cardiac failure concurrently; 4.8% developed renal impairment; and 2.8% developed chronic liver disease. The development of contraindications rarely resulted in discontinuation of metformin, for example only 17.5% and 25% stopped metformin after admission with acute myocardial infarction and development of renal impairment, respectively. In total, 24.5% of subjects receiving metformin, 6.4% of all people with Type 2 diabetes, had contraindications to its use. There was one episode of lactic acidosis in 4600 patient years.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> This population\u2010based study shows that 24.5% of patients prescribed metformin have contraindications to its use. Development of contraindications rarely results in discontinuation of metformin therapy<jats:bold>.<\/jats:bold> Despite this, lactic acidosis remains rare.<\/jats:p><jats:p>Diabet. Med. 18, 483\u2013488 (2001)<\/jats:p>","DOI":"10.1046\/j.1464-5491.2001.00509.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T14:50:31Z","timestamp":1047394231000},"page":"483-488","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":153,"title":["Contraindications to metformin therapy in patients with Type 2 diabetes\u2014a population\u2010based study of adherence to prescribing guidelines"],"prefix":"10.1111","volume":"18","author":[{"given":"A. M.","family":"Emslie\u2010Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. I. R.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M. M.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the DARTS\/MEMO Collaboration","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(98)07037-8"},{"key":"e_1_2_7_3_2","unstructured":"Lipha Pharmaceuticals.Glucophage Pharmaceutical Data Sheet 1999."},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.1999.00006.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7107.524"},{"key":"e_1_2_7_6_2","first-page":"245","volume-title":"Pharmacoepidemiology.","author":"MacDonald TM","year":"1994"},{"key":"e_1_2_7_7_2","first-page":"177","article-title":"The Tayside medicines monitoring unit (MEMO): a record\u2010linkage system for pharmacovigilance","volume":"9","author":"Evans JMM","year":"1995","journal-title":"Pharm Med"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01263443"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199508313330903"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.11.4059"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050184"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602293340906"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.15.6.755"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02440866"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920060-00003"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.10.1587"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.10.1659"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.1999.00115.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.6.925"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1099-1557(199809\/10)7:5<311::aid-pds371>3.3.co;2-f"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1464-5491.2001.00509.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1464-5491.2001.00509.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1464-5491.2001.00509.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T20:59:38Z","timestamp":1697576378000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1464-5491.2001.00509.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1046\/j.1464-5491.2001.00509.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1464-5491.2001.00509.x","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]},"assertion":[{"value":"2001-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}